Alucent Biomedical Inc., which is developing a restorative therapy for peripheral artery disease (PAD), completed a $35 million series B financing led by a multinational strategic investor. The funds will be used to complete clinical studies of the Alucent Natural Vascular Scaffolding (AlucentNVS) vessel restoration system with photoactivated linking, the company’s first product.
Ionpath Inc., a developer of high-definition spatial proteomics, scored $18 million in a series B funding round led by Samsara Biocapital. The round also included global mass spectrometry leader Bruker Corp. as a new investor. Menlo Park, Calif.-based Ionpath plans to use the investment for continued development and deployment of the company’s Multiplexed Ion Beam Imaging (MIBI) technology, which provides quantitative protein imaging at a subcellular level.
Nutcracker Therapeutics Inc., a startup developing a "push-button GMP-in-a-box" platform to manufacture mRNA therapeutics, has raised $60 million in series B financing led by Arch Venture Partners.
Immune Regulation Ltd., a U.S.-U.K. venture advancing peptide-based therapies for rheumatoid arthritis and allergic diseases, has closed a £40.6 million (US$53.4 million) series B financing that will support its preparation for multiple phase II studies next year, as well as an evaluation of one candidate in COVID-19-related acute respiratory distress syndrome. Morningside Ventures led the round, along with existing shareholders, including London-based 24Haymarket.
Palleon Pharmaceuticals Inc. CEO and founder Jim Broderick told BioWorld that the just-raised $100 million in series B money leaves the firm well positioned to push its lead oncology compound into the clinic next year, bolstered by a widely gathered team of experts – “almost a consortium” – in glycan mediation.
In the more than two years since Casma Therapeutics Inc. raised its series A and completed its new $50 million series B, the company has advanced its agonist program for treating muscular dystrophy and identified new targets.
Rain Therapeutics Inc., a California company developing targeted cancer therapies with a biomarker-based strategy, has raised a $63 million series B round led by Boxer Capital to support its development of the small-molecule MDM2 inhibitor RAIN-32 (milademetan) for the potential treatment for liposarcoma and other cancers.
Exo Imaging Inc. closed a $40 million series B+ funding round that is earmarked to help with the development of a hand-held ultrasound device and cloud-based workflow software platform. The funding follows a series B round in August 2019 that reeled in $35 million and brings the company’s total raise to nearly $100 million.
With an eye toward launching its first product, Mobilion Systems Inc. has revealed a $35 million series B funding round led by Amoon. Todd Sone, partner at Amoon who also is joining the company’s board, highlighted the duo’s common vision to develop technologies that offer high resolution and speed.
RSS
